Sangamo BioSciences | SGMO - Trade Debtors


Sangamo BioSciences reported $581K in Trade Debtors for its fiscal quarter ending in June of 2024.





Trade Debtors Change Date
Alaunos Therapeutics USD 2K 0 Jun/2025
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
Alterity Therapeutics Limited AUD 4.57M 1.42M Dec/2025
Amgen USD 9.14B 432M Mar/2026
Bayer EUR 18.55B 4.36B Mar/2026
BioCryst Pharmaceuticals USD 106.82M 15.49M Dec/2025
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Cipla INR 62.19B 12.42B Mar/2026
Clal Biotechnology ILS 3.75M 186K Dec/2022
Compugen USD 2.34M 44K Mar/2026
CSL USD 4.32B 1.35B Dec/2025
Gilead Sciences USD 4.74B 172M Mar/2026
GlaxoSmithKline GBP 7.94B 178M Mar/2026
Grifols EUR 1B 285.88M Dec/2025
Ionis Pharmaceuticals USD 74M 8M Mar/2026
J&J USD 22.54B 1.21B Mar/2026
Karyopharm Therapeutics USD 26.18M 5.6M Dec/2025
Merck USD 11.78B 345M Dec/2025
Novartis USD 9.6B 2.69B Mar/2026
Omeros USD 8.08M 440K Jun/2024
Pfizer USD 16.17B 332M Mar/2026
Roche Holding CHF 13.34B 1.44B Jun/2026
Sangamo BioSciences USD 581K 110K Jun/2024
Sanofi EUR 482M 85M Mar/2026
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
Tectonic Therapeutic USD 0 270K Dec/2023
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026